

1 **Title:** Diagnostic serology test comparison for Q fever and Rift Valley fever in humans and livestock
2 from pastoral communities

3

4 **Authors:** Valerie Hungerbühler¹, Ranya Özcelik¹, Mahamat Fayiz Abakar², Fatima Abdelrazak
5 Zakaria², Martin Eiden³, Sonja Hartnack⁴, Pidou Kimala², Sonja Kittl⁵, Janine Michel⁶, Franziska
6 Suter-Riniker⁷, Salome Dürr¹

7 **Affiliations**

8 ¹Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland

9 ²Institut de Recherche en Elevage pour le Développement, N'Djamena, Chad

10 ³Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald – Insel Riems,
11 Germany

12 ⁴Section of Epidemiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland

13 ⁵ZOBA, Center for Zoonoses, Animal Bacterial Diseases and Antimicrobial, Vetsuisse Faculty,
14 University of Bern, Bern, Switzerland

15 ⁶Robert Koch Institute, Centre for Biological Threats and Special Pathogens, Highly Pathogenic
16 Viruses, Berlin, Germany

17 ⁷IFIK, Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland

18

19 **Correspondence:** Valerie Hungerbühler

20 Veterinary Public Health Institute, Vetsuisse Faculty

21 University of Bern

22 Schwarzenburgstrasse 161

23 3097 Liebefeld, Switzerland

24 M: +41 77 423 18 62

25 E: valerie.hungerbuehler@vetsuisse.unibe.ch

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Abstract

28

29 Q fever (QF) and Rift Valley fever (RVF) are endemic zoonotic diseases in African countries, causing
30 significant health and economic burdens. Accurate prevalence estimates, crucial for disease control, rely
31 on robust diagnostic tests. While enzyme-linked immunosorbent assays (ELISA) are not the gold
32 standard, they offer rapid, cost-effective, and practical alternatives. However, varying results from
33 different tests and laboratories can complicate comparing epidemiological studies. This study aimed to
34 assess the agreement of test results for QF and RVF in humans and livestock across different laboratory
35 conditions and, for humans, different types of diagnostic tests.

36 We measured inter-laboratory agreement using concordance, Cohen's kappa, and prevalence and bias-
37 adjusted kappa (PABAK) on 91 human and 102 livestock samples collected from rural regions in Chad.
38 The samples were tested using ELISA in Chad, and indirect immunofluorescence assay (IFA) (for
39 human QF and RVF) and ELISA (for livestock QF and RVF) in Switzerland and Germany. Additionally,
40 we examined demographic factors influencing test agreement, including district, setting (village vs.
41 camp), sex, age, and livestock species of the sampled individuals.

42 The inter-laboratory agreement ranged from fair to moderate. For humans, QF concordance was 62.5%,
43 Cohen's kappa was 0.31, RVF concordance was 81.1%, and Cohen's kappa was 0.52. For livestock, QF
44 concordance was 92.3%, Cohen's kappa was 0.59, RVF concordance was 94.0%, and Cohen's kappa
45 was 0.59. Multivariable analysis revealed that QF test agreement is significantly higher in younger
46 humans and people living in villages compared to camps and tends to be higher in livestock from
47 Danamadji compared to Yao, and in small ruminants compared to cattle. Additionally, RVF agreement
48 was found to be higher in younger humans.

49 Our findings emphasize the need to consider sample conditions, test performance, and influencing
50 factors when conducting and interpreting epidemiological seroprevalence studies.

51

52 Author Summary

53

54 Q fever (QF) and Rift Valley fever (RVF) are zoonotic diseases that can be transmitted from animals to
55 humans, causing health problems and economic losses in African countries. While various diagnostic
56 tests for these diseases are available, they can be impractical, especially in resource-limited settings.

57 For this study, human and livestock samples from Chad were first tested in a local laboratory using a
58 routine test. The same samples were then sent to laboratories in Germany or Switzerland for retesting,
59 using the same test type for livestock and a different test type for human samples.

60 We analysed the agreement between the test results and investigated the influence of the demographic
61 characteristics of the sampled individual on this agreement. Our findings are crucial as they reveal
62 discrepancies in test results, even though the samples originated from the same individuals. Additionally,
63 we found that factors such as the age of the sampled individual influenced test agreement.

64 This study underscores the importance of considering sample conditions, test performance, and
65 influencing factors when conducting and interpreting disease prevalence studies. Enhancing diagnostic
66 procedures will aid in more effective disease control management, benefiting local communities and
67 global health efforts.

68

69 1. Introduction

70

71 Q Fever (QF) and Rift Valley fever (RVF) are zoonotic diseases prevalent in several African countries.
72 Reported prevalence rates range from 7.8% to 39% for QF and 9.5% to 44.2% for RVF in livestock, and
73 from 27% to 49.2% for QF and 13.2% to 28.4% for RVF in humans [1–4]. QF and RVF impact human
74 health by causing a flu-like syndrome that can lead to a range of severe manifestations. QF and RVF
75 also result in significant production losses in animals due to abortions [5,6].

76 High-quality samples and robust diagnostic tests are essential for obtaining accurate prevalence
77 estimates. Epidemiological studies play a critical role in generating the necessary data, subsequently
78 influencing government prioritization of health interventions [7,8]. This prioritization is fundamental to
79 effective disease control.

80 For QF diagnostics, the indirect immunofluorescence assay (IFA) can differentiate between acute and
81 chronic infections and is regarded as the gold standard test for humans [9,10]. Commercial kits are not
82 available for veterinary use [11]. The enzyme-linked immunosorbent assay (ELISA) is the most widely
83 used test and is recommended by the WOA (World Organisation for Animal Health) for rapid routine
84 screening and large-scale epidemiological studies in ruminant populations [8]. For RVF, the virus
85 neutralisation test (VNT) is the most specific diagnostic serological test, but it can only be performed
86 with live viruses and is not recommended for use in laboratories without appropriate biosecurity
87 facilities and vaccinated personnel [6,7]. For both diseases, ELISAs offer a rapid, cost-effective, and
88 practical alternative with less stringent biosafety requirements, making them suitable for routine use in
89 low- and middle-income countries (LMIC) [7,8].

90 The use of ELISA in some studies and the gold standard test, which may differ between countries, in
91 others can lead to discrepancies in estimated prevalence, making comparisons challenging; thus,
92 harmonized monitoring and reporting schemes for QF and RVF have been proposed to enable consistent
93 comparisons over time and across countries [12–14].

94 Several studies have assessed the inter-test agreement of ELISA for QF and RVF compared to other
95 diagnostic tests, reporting variable agreement ranging from poor to good for QF and from good to
96 excellent for RVF [15–21]. Diagnostic test validation can be achieved through various methods,

97 including assessing the agreement between different tests without assuming one as the gold standard
98 [22]. Concordance, the proportion of test results in agreement over the number of all tests performed, is
99 a straightforward measure but does not account for agreement beyond chance. Therefore, Cohen's kappa
100 statistic, which adjusts for random matches, is often used to measure the agreement between two test
101 results [22]. Cohen's kappa values range from zero (agreement is equal to that expected by chance) to
102 one (complete agreement beyond chance), with benchmarks between agreement categories varying
103 among authors [23–25]. Although Cohen's kappa is a standard measure, it has limitations such as
104 prevalence and bias effects. Prevalence effects arise when the proportion of positive results deviates
105 significantly from 50% [26]. The effect of prevalence depends on the method of modeling agreement
106 and can substantially reduce kappa values [26]. Bias effects occur when there is a disparity in the
107 proportion of positive results between the two tests, which leads to reduced kappa values [26]. To
108 address these effects, the prevalence- and bias-adjusted kappa (PABAK) can be calculated [27,28].
109 The reasons for disagreement between diagnostic tests have rarely been thoroughly investigated.
110 Potential factors include poor sample quality, variability in tests used, and discrepancies arising from
111 the same test being conducted in different laboratories [17,21,29]. Additionally, biological factors such
112 as age, sex, other diseases, and species may influence the consistency of test results for the same sample.
113 Previous studies have suggested associations between test performance and variables such as region,
114 age, and livestock species [30–32]. However, these studies have not provided conclusive evidence or
115 statistical significance.
116 The objective of this study was to assess the inter-laboratory agreement, measured by the concordance,
117 Cohen's kappa, and PABAK, of results obtained from commercial ELISA tests conducted in a laboratory
118 in Chad and results obtained from ELISA and indirect IFA tests for livestock and human samples
119 respectively, performed in laboratories in Germany and Switzerland. Additionally, we evaluated the
120 influence of demographic factors on the agreement between the two test results. The study enhances our
121 understanding of the inter-laboratory agreement of diagnostic test results across laboratory conditions
122 and, for humans, test types, which is crucial for accurately interpreting results from epidemiological
123 seroprevalence studies.

124 2. Material and Methods

125

126 2.1 Ethics statement

127 The study has been submitted to and approved by the Ethics Committee of Northwest and Central
128 Switzerland (EKNZ) (project id 2017-00884) and by the Comité National de Bioéthique du Tchad
129 (CNB-Tchad) (project id 134/PR/MESRS/CNBT/2018). Formal written consent was obtained from
130 study participants and animal owners after we presented our study to the community and before data
131 collection occurred.

132

133 2.2 Sample collection and laboratory analysis in Chad


134 The samples analysed in this study were collected between January and February 2018 [4]. In brief, a
135 cross-sectional study in livestock (cattle, sheep, goats, horses, and donkeys) and human populations was
136 conducted in the two rural health districts, Yao and Danamadji, in Chad. Multistage cluster sampling
137 was used, with villages and nomadic camps serving as cluster units. In Danamadji and Yao, respectively,
138 blood samples were collected from apparently healthy 571 and 389 humans and 560 and 483 livestock.
139 The samples were subsequently analysed at the Institut de Recherche en Élevage pour le Développement
140 (IREED) in N'Djamena, Chad. Livestock and human samples were analysed using different indirect
141 ELISAs: ID Screen® Q Fever Indirect Multi-species ELISA from IDvet for livestock and the Panbio®
142 Coxiella burnetii IgG ELISA from Abbott for humans. For RVF, a competitive ELISA (ID Screen®
143 Rift Valley Fever Competition Multi-species from IDvet) was used for human and livestock samples.
144 The diagnostic test procedure and thresholds were applied according to the manufacturer's protocols
145 without modification (Table S1 – Table S3). Equivocal samples were retested once.

146

147 2.3 Diagnostic testing in Switzerland and Germany

148 Following the initial diagnostic analysis at IRED, 10% of the human and livestock samples from each
149 region were randomly selected and sent to laboratories in Switzerland and Germany in 2021 for repeated
150 diagnostic analysis for QF and RVF, respectively. In Switzerland, two indirect ELISAs (IDEXX Q Fever
151 IgG Antibody and ID Screen® Q Fever Indirect Multispecies from IDvet) were used at the Center for

152 Zoonoses, Animal Bacterial Diseases, and Antimicrobial Resistance (ZOBA) for QF diagnostics in
 153 livestock samples (ruminants and equids, respectively). At the Institute for Infectious Diseases (IFIK)
 154 of the University of Bern, an indirect IFA (Q Fever IFA IgG assay from Focus Diagnostics, US) was
 155 used for QF diagnostics in human samples. For RVF, livestock samples were analysed using a
 156 competitive ELISA (ID Screen® Rift Valley Fever Competition Multi-species ELISA from IDvet) at
 157 the Federal Research Institute for Animal Health (FLI), and human samples were analysed using an
 158 indirect IFA (Anti-Rift-Tal-Fieber-Viren-IIFT [IgG] from EUROIMMUN) at the Robert Koch Institute
 159 (RKI). The diagnostic test procedure and thresholds were applied according to the manufacturer's
 160 protocols without modification (Table S1, Table S3, Table S4 – Table S6). Equivocal samples were not
 161 retested.
 162



163
 164 **Fig 1: Sample collection and laboratory analysis at IRED in Chad and diagnostic testing in Switzerland and**
 165 **Germany. The numbers of samples at each stage are indicated.**

166
 167 2.4 Statistical analysis

168 The inter-laboratory agreement of the test results from Chad and Switzerland or Germany was evaluated
169 using concordance, Cohen’s Kappa, and PABAK for each of the four datasets: QF results in human
170 samples, QF results in livestock samples, RVF results in human samples, and RVF results in livestock
171 samples. Cohen's kappa and PABAK values were interpreted according to the standard scale: 'fair'
172 agreement (kappa = 0.21–0.40), 'moderate' agreement (kappa = 0.41–0.60), 'substantial' agreement
173 (kappa = 0.61–0.80), and 'almost perfect' agreement (kappa > 0.80) [25].

174 In addition, we investigated factors associated with test agreement by assigning to each sample a value
175 of 0 if there was disagreement between the two test results (i.e., negative in Chad and positive in
176 Switzerland/Germany, or the opposite) and 1 if the test results were consistent (i.e., both positive or both
177 negative). This binary outcome was used as the dependent variable in logistic regression models to
178 identify the statistical association between test agreement and demographic factors, including the district
179 (Yao *versus* Danamadji) and setting (village *versus* camp) where the sample was collected, and sex, age,
180 and livestock species (cattle, small ruminants, and equids) of the sampled individual. The variable age
181 was analysed in two ways, as a continuous and as a categorical variable. For the continuous variable, a
182 unit of 1 year was used for livestock and of 10 years for humans. For the categorical variable, samples
183 were stratified as < 2 years (age group 1), 2–3 years (age group 2), 4 years and older (age group 3) for
184 livestock, and < 30 years (age group 1), 30–39 years (age group 2), 40–60 years (age group 3), 61 years
185 and older (age group 4) for humans.

186 Univariable logistic regressions were initially performed to assess individual predictors. In cases where
187 the univariable model was infeasible due to perfect agreement in one group, Chi-square tests were
188 applied. Odds ratios (OR) and their corresponding 95% confidence intervals were calculated for these
189 analyses. To consider potential interdependencies between the variables, we applied multivariable
190 logistic regressions to estimate adjusted coefficients and OR. We included all variables and selected age
191 as categorical variable.

192 Statistical calculations, modeling, and data visualization were conducted in R (version 4.2.2). The
193 package “irr” was used to calculate the concordance and Cohen’s kappa. The package “vcd” was used
194 to obtain confidence intervals of Cohen’s kappa, computed using the standard method based on normal
195 approximation [33]. The `epi.kappa()` function from the “epiR” package was used to calculate PABAK

196 and corresponding confidence intervals. The confidence intervals for the OR were calculated using the
197 output values of the associated regression model and the functions $\exp(\text{coefficients}(\text{model}))$ for the
198 upper CI and $\exp(\text{confint.default}(\text{model}))$ for the lower CI was used.

199

200 3. Results

201

202 3.1 Study population and samples

203 From 103 livestock and 96 human samples sent to Switzerland and Germany, not all of them could be
 204 used for statistical analysis. Reasons for excluding them include unsuccessful matching of test identity
 205 due to labelling errors, missing serum upon arrival at the laboratory, and equivocal results (Table1).
 206 Finally, 91 human and 102 livestock samples were tested for either one of both tests, depending on the
 207 availability of serum (Table S7 and Table 1, Fig. 1).

208

209 **Table 1: Overview of diagnostic tests from Chad and Switzerland (CH) or Germany (GE).**

Disease	QF ¹		RVF ²	
Samples	Livestock	Humans	Livestock	Humans
Laboratory, Chad	IRED ³	IRED ³	IRED ³	IRED ³
Test 1, Chad	ID Screen® Q Fever Indirect Multi- Species	Panbio® Coxiella burnetii IgG ELISA	ID Screen® Rift Valley Fever Competition Multi-species	ID Screen® Rift Valley Fever Competition Multi-species
Laboratory, CH/GE	ZOBA (CH) ⁴	IFIK (CH) ⁵	FLI (GE) ⁶	RKI (GE) ⁷
Test 2, CH/GE	IDEXX Q Fever Ab Test and the ID Screen® Q Fever Indirect Multispecies	Focus Diagnostics Q Fever IFA IgG assay	ID Screen® Rift Valley Fever Competition Multi-species	Indirect immunofluorescence test (IIFT)
Initial number of samples shipped to CH/GE	103	96	103	96
Excluded samples from test 2 due to missing serum	2	8	0	4
Equivocal results during test 2	8	14	2	0
Non-matchable	2	2	1	2
Number of samples used for agreement testing	91	72	100	90

210 ¹Q Fever

211 ²Rift Valley Fever

212 ³Institut de Recherche en Elevage pour le Développement, Chad

213 ⁴Center for Zoonoses, Animal Bacterial Diseases and Antimicrobial, Switzerland (CH)

214 ⁵Institute for Infectious Diseases, Switzerland (CH)
 215 ⁶Friedrich-Loeffler-Institut, Germany (GE)
 216 ⁷Robert Koch Institut, Germany (GE)
 217

218 Of the 91 human and 102 livestock samples that were used to perform the intra-laboratory test agreement
 219 analysis, most samples were collected in Danamadji, with 62% of human samples and 57% of livestock
 220 samples originating from this region (Table S7). Fifty-six percent of human samples and 58% of
 221 livestock samples were collected from camps. The sex distribution was uneven, with 70% of human
 222 samples being men and 70% of livestock samples being females. Among humans, age groups 1-3 were
 223 evenly represented (30%, 28%, 33%), while only 9% belonged to age group 4. In livestock, 50% of the
 224 samples were from age group 2, with 17% and 33% from age groups 1 and 3, respectively. Most
 225 livestock samples were from cattle (46%), followed by small ruminants (41%) and equids (13%).
 226

227 3.2 Diagnostic tests agreement

228 3.2.1 Level of inter-laboratory test agreement

229 Concordance values ranged from 62.5% to 94% (Table 2). Cohen's kappa values, which ranged from
 230 0.31 to 0.59, indicated that livestock QF and RVF, and human RVF tests had 'moderate' agreement,
 231 while human QF tests had 'fair' agreement (Table 2). PABAK values showed that the livestock QF and
 232 RVF tests had 'almost perfect' agreement, the human RVF test had 'substantial' agreement, and the
 233 human QF tests had 'fair' agreement (Table 2).
 234

235 **Table 2: Analyses of test agreement (concordance and Cohen's kappa) of samples tested in an inter-**
 236 **laboratory test agreement study.**

	Switzerland				Germany			
	QF livestock		QF humans		RVF livestock		RVF humans	
Chad	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg
Pos	6	3	22	3	5	4	16	9
Neg	4	78	24	23	2	89	8	57
Concordance (%)	92.3		62.5		94.0		81.1	
Cohen's kappa value (95% CI)	0.59 (0.31, 0.86)		0.31 (0.13, 0.49)		0.59 (0.30, 0.89)		0.52 (0.33, 0.72)	

PABAK value	0.846 (0.696, 0.937)	0.25 (0.006, 0.473)	0.88 (0.748, 0.955)	0.622 (0.43, 0.771)
(95% CI)				

237

238

239 3.2.1 Influence of factors on inter-laboratory test agreement

240 For QF in livestock, none of the investigated demographic factors significantly impacted the agreement
241 between the two test results in both univariable and multivariable analyses (Table S8 and Table 3).

242 However, some notable trends ($p < 0.15$) emerged: small ruminants tended to show better agreement
243 than cattle, and samples from Yao showed lower agreement compared to those from Danamadji (Table

244 3). For QF in humans, samples from villages had significantly higher agreement compared to those from
245 camps, with odds of agreement being 13.4 times higher (Table 3). Additionally, older age groups had

246 significantly lower agreement compared to the youngest age group (Table 3).

247 For RVF in humans and livestock, none of the demographic factors significantly influenced test
248 agreement. However, some trends were observed for RVF test agreement in humans, with older age

249 groups showing lower agreement compared to the youngest age group (Table 3).

250 Across diseases and populations, there was a consistent trend of lower agreement with increasing age,
251 which was significant for human QF and almost reached significance for human RVF (Table 3, Fig. 2).

252 For livestock RVF tests, the odds ratio for agreement was also lower in older age groups, although the
253 p-value was 0.26 (Table 3).

254 **Table 3: Results of multivariable logistic regression models investigating the effect of demographic factors**
255 **as independent variables on the inter-laboratory test agreement of Q fever (QF) and Rift Valley Fever**
256 **(RVF) in humans and livestock. Goodness of fit of the models are presented as pseudo-R-squared (R^2).**

257 **Bold p-values indicate significance based on a threshold of 0.05.**


Independent variable (OR and 95% CI)	Switzerland		Germany	
	QF livestock	QF humans	RVF livestock	RVF humans
P-value (P)				
District	Yao:	Yao:	Yao:	Yao:
(Reference: Danamadji)	0.14 (0.01, 1.74)	1.38 (0.38, 4.99)	4.99 (0.41, 60.49)	1.37 (0.37, 5.04)
	P = 0.13	P = 0.63	P = 0.21	P = 0.64

Setting (Reference: camp)	Village: 0.34 (0.05, 2.06) P = 0.24	Village: 13.35 (3.20, 55.86) P = 0.0004	Village: 0.32 (0.04, 2.43) P = 0.27	Village: 1.85 (0.58, 5.93) P = 0.30
Species (Reference: cattle)	Equids: 5.51 (0.29, 103.21) P = 0.25	-	Equids: Inf (perfect agreement)	-
	Small ruminants: 6.26 (0.59, 65.76) P = 0.13		Small ruminants: 0.65 (0.09, 4.78) P = 0.67	
Age group (Reference: age group 1/group 2*)	Group 2: 1.30 (0.10, 17.39) P = 0.84	Group 2: 0.67 (0.15, 3.07) P = 0.61	Group 1*: Inf (perfect agreement)	Group 2: 0.62 (0.12, 3.16) P = 0.57
	Group 3: 0.93 (0.06, 14.38) P = 0.96	Group 3: 0.14 (0.03, 0.82) P = 0.03	Group 3*: 0.30 (0.04, 2.41) P = 0.26	Group 3: 0.32 (0.07, 1.47) P = 0.14
		Group 4: 0.09 (0.01, 0.83) P = 0.03		Group 4: 0.16 (0.02, 1.14) P = 0.07
Sex (Reference: male)	Female: 0.38 (0.03, 4.61) P = 0.45	Female: 0.82 (0.20, 3.38) P = 0.78	Female: 0 (perfect agreement in males)	Female: 1.01 (0.27, 3.86) P = 0.99
R²	0.23	0.35	0.28	0.09

258

259

260



261

262

263 **Fig. 2:** In the mosaic plot illustrating the association between age groups and inter-laboratory test
264 agreement, the widths of the adjacent rectangles represent the proportion of individuals within each age
265 group. The heights of the rectangles represent the proportion of individuals within each age group who
266 exhibit a specific test agreement outcome (concordant or discrepant).

267

268 4. Discussion

269

270 QF and RVF are important zoonotic diseases in sub-Saharan Africa, for which several epidemiological
271 questions remain open. Reliable diagnostics are highly relevant for generating prevalence data, and it
272 has been emphasized that there is a need for cost-effective surveillance tools for low and middle-income
273 countries [5,34].

274 Our study revealed varying levels of test agreement, ranging from fair to moderate (Cohen's kappa) or
275 almost perfect when considering PABAK. The good inter-laboratory agreement of livestock test results
276 for RVF was in line with other studies on RVF test agreement, although it is important to note that
277 literature is scarce [19,20]. The inter-laboratory agreement for livestock QF was slightly better than
278 expected, based on previous studies that assessed ELISA's agreement with different test types
279 [15,17,18]. We observed a notably lower agreement for human tests for both diseases that can be
280 attributed to using two different tests for human samples, ELISA in Chad and indirect IFA in
281 Switzerland or Germany. Previous studies have shown varying sensitivities and specificities of the
282 commercial diagnostic test for QF used in this study (Panbio®), ranging from 71% to 100% [10,35–37].
283 In these studies, indirect IFA was used as a reference method to evaluate the ELISA, revealing varying
284 agreement between the results of the two tests. The variability in sensitivity for the same test raises the
285 question of whether it is due to the scope for interpretation in indirect IFA, which is considered a
286 challenge, even though indirect IFA is regarded as the gold standard for human QF diagnostics [5,8]. A
287 study that compared QF indirect IFA results from different reference centres in three countries (United
288 Kingdom, France, and Australia) found a concordance between the indirect IFA results of only 35%
289 [38]. Our results presented here reflect this uncertainty and underline the complexity of QF diagnostics
290 [5,8,39]. In addition, commercial QF ELISA kits, unlike indirect IFA, cannot distinguish between acute
291 or chronic infection and vaccination, which can sometimes lead to misinterpretation and discordant test
292 results, even between different ELISA kits [21,40]. For RVF, lower inter-laboratory agreement for
293 human tests compared to livestock tests can also be attributed to using different tests in Chad (ELISA)
294 and Germany (indirect IFA). The literature on RVF test agreement, particularly for human diagnostics,
295 is notably scarce.

296 A possible reason for disagreement between test results could be the hemolytic quality of some of our
297 samples. Although we lack quantitative information on the quality of the individual samples in our study,
298 laboratory staff in Switzerland and Germany indicated that haemolysis was a concern. In recent
299 literature, haemolysis in specimens was reported to be the most common cause of test result
300 discrepancies in clinical laboratories [41]. There are many in vitro causes of haemolysis, mostly pre-
301 analytical problems such as incorrect procedures and/or materials used in blood collection, while
302 transport, processing, and storage account for only a minority of cases [42]. This limitation shows the
303 importance of careful planning and execution of the pre-analytical phase, especially in prevalence
304 studies where the outcome can be influenced by the quality of the sample material. Nevertheless, it is
305 crucial to recognize the challenges associated with collecting samples under difficult field conditions,
306 where access to centrifuges may be limited until several days after blood sampling. In addition, the
307 samples in our study were stored for 2.5 years with repeated freeze-thaw cycles between the performance
308 of the two tests for some of the samples, which probably affected sample quality. Therefore, extended
309 transport to secondary laboratories for subsequent analysis can additionally adversely affect sample
310 quality. We emphasize the importance of considering these challenges when discussing the outcomes of
311 epidemiological prevalence studies or diagnostic test evaluation studies.

312 Our results demonstrate a statistical relationship between test agreement and age of the sampled
313 individuals, with higher agreement observed in younger individuals for both diseases and in humans and
314 livestock. This finding aligns with a study by de Bronsvort et al. (2019), which suggested that lower
315 agreement in older individuals may be due to their higher likelihood of previous exposure to other
316 pathogens over their lifetime [30]. This may result in cross-reactivity in serological tests, making
317 serological differentiation between diseases more difficult [39]. Cross-reactions caused by antibodies
318 provoked by other pathogens, such as *C. burnetii* antigens, the agent causing QF, with antibodies
319 produced against *Bartonella spp.*, *Legionella spp.*, and *Chlamydiae spp.* has been reported [43–45], or
320 RVF virus antigens with antibodies produced against Rio Grande virus [46–48]. Furthermore, with
321 increasing age, the likelihood of exposure to the causative agent of QF and RVF increases [49,50], as
322 does the chance of having residual antibodies titres against these diseases in the blood [6,51–53]. In
323 addition in QF, antigen-lipopolysaccharide complexes remaining in the host after infection with *C.*

324 *burnetii* can trigger humoral and cell-mediated immune responses, producing interfering antibodies
325 [54,55]. Such antibody titres can potentially produce ambiguous results that are neither clearly positive
326 nor negative, leading to misinterpretation and discordant test results. These findings underscore the need
327 for further research to develop age-specific diagnostic protocols and improve test accuracy across
328 diverse populations.

329 The district-level analysis showed a trend toward higher agreement for livestock QF tests in samples
330 from Danamadji compared to Yao. This regional variation may be influenced by varying local
331 environmental conditions, disease prevalence, or livestock management practices. However, we did not
332 capture such information, so we were not able to identify a potential latent factor that can explain the
333 difference in test agreement detected for the two regions. Continuing with the focus on sampling
334 location, the sample collection setting (village versus camp) was identified as a significant factor in the
335 multivariable model for human QF test agreement. One hypothesis for this finding is that villages
336 generally have shorter distances from the sampling location to the laboratory, allowing for more
337 appropriate storage conditions compared to remote camps. This shorter travel time likely preserves
338 sample integrity, resulting in higher test agreement. The significant role of the setting variable suggests
339 that environmental and logistical factors may be crucial for diagnostic test result interpretation, although
340 we did not observe the influence of the setting for RVF in humans nor for livestock species. Future
341 studies should investigate the impact of environmental and logistical factors on test results and gather
342 detailed data on local conditions and practices that affect sample quality and test agreement.

343 Small ruminants exhibited a trend towards higher agreement in QF test results compared to cattle. In a
344 different type of QF ELISA, Stellfeld et al. (2020) observed significant differences in the ranges of
345 OD₄₅₀ values obtained from sera of sheep, goats, and cattle [56]. Sheep exhibited a large range of OD₄₅₀
346 values, whereas cattle showed a smaller range [56]. Greater distribution between OD₄₅₀ values allows
347 for more precise grading of ELISA results, which may explain the better inter-test agreement for small
348 ruminants compared to cattle. These differences in OD₄₅₀ ranges are likely due to species-specific
349 immune responses to *C. burnetii*, suggesting varying immune reactions among ruminant species [56].

350 Although females showed lower inter-laboratory test agreement compared to males for both diseases
351 and populations, the high p-values and wide confidence intervals of OR indicate that these results are

352 not statistically robust and should be interpreted with caution. Epidemiological studies suggest similar
353 QF exposure rates between genders, but symptoms are 2.5 times more common in men [5]. This
354 variability in inflammatory immune response between genders [57–60] could lead to less clear antibody
355 titers in samples from females, a hypothesis that should be tested by further studies investigating the
356 influence of demographic factors on diagnostic test agreement.

357 Conclusion

358 Our study highlights the variability in inter-laboratory diagnostic test agreement for QF and RVF
359 serology in humans and livestock based on samples collected in Chad. Despite differences in
360 laboratories, personnel, and test types, test agreements ranged from fair to moderate (Cohen's kappa) or
361 almost perfect considering PABAK. Given the reliance on serological profiles for QF and RVF
362 epidemiological studies, it is crucial to consider factors that may complicate accurate diagnosis. We
363 identified that human QF test agreement was significantly higher in individuals living in villages and
364 younger individuals, with the latter trend also observed in human RVF tests. Our findings emphasize
365 the need to recognize that diagnostic tests may yield varying results, impacting the outcome and
366 interpretation of disease prevalence studies.

367

368

369

370

371

372

373

374

375

376

377 Declaration of generative AI and AI-assisted technologies in the writing process

378

379 While preparing this work, the author used ChatGPT to correct the English in the revised sentences

380 (using the command: 'correct the English'). After using this tool, the author reviewed and edited the

381 content as needed and takes full responsibility for the content of the publication.

382

383 References

384

385 [1] Fayiz Abakar M, Naré NB, Schelling E, Hattendorf J, Alfaroukh IO, Zinsstag J. Seroprevalence of
386 Rift Valley fever, Q fever, and brucellosis in ruminants on the southeastern shore of Lake
387 Chad. *Vector-Borne and Zoonotic Diseases* 2014;14: 757–62. doi: 10.1089/VBZ.2014.1585.

388 [2] Blomström AL, Scharin I, Stenberg H, Figueiredo J, Nhambirre O, Abilio A, et al.
389 Seroprevalence of Rift Valley fever virus in sheep and goats in Zambézia, Mozambique. *Infect
390 Ecol Epidemiol* 2016;6. doi: 10.3402/IEE.V6.31343.

391 [3] Ibrahim M, Schelling E, Zinsstag J, Hattendorf J, Andargie E, Tschopp R. Sero-prevalence of
392 brucellosis, Q-fever and Rift Valley fever in humans and livestock in Somali Region, Ethiopia.
393 *PLoS Negl Trop Dis* 2021;15: 1–18. doi: 10.1371/JOURNAL.PNTD.0008100.

394 [4] Özcelik R, Abakar MF, Counotte MJ, Zakaria FA, Kimala P, Issa R, et al. Seroprevalence and
395 associated risk factors of brucellosis, Rift Valley fever and Q fever among settled and mobile
396 agro-pastoralist communities and their livestock in Chad. *PLoS Negl Trop Dis* 2023;17:
397 e0011395. doi: 10.1371/JOURNAL.PNTD.0011395.

398 [5] Eldin C, Mélenotte C, Mediannikov O, Ghigo E, Million M, Edouard S, et al. From Q fever to
399 *Coxiella burnetii* infection: A paradigm change. *Clin Microbiol Rev* 2017;30: 115–90. doi:
400 10.1128/CMR.00045-16.

401 [6] Wright D, Kortekaas J, Bowden TA, Warimwe GM. Rift Valley fever: biology and epidemiology.
402 *J Gen Virol* 2019;100: 1187–99. doi: 10.1099/JGV.0.001296.

403 [7] Rift Valley fever - WOA - World Organisation for Animal Health [cited 17 June 2024].
404 Available from: <https://www.woah.org/en/disease/rift-valley-fever/>.

405 [8] Q fever - WOA - World Organisation for Animal Health [cited 17 June 2024]. Available from:
406 <https://www.woah.org/en/disease/q-fever/>.

407 [9] Imbert G, La Scola B. Diagnosis of Q fever using indirect microimmunofluorescence. *Methods
408 Mol Biol* 2006;345: 197–202. doi: 10.1385/1-59745-143-6:197.

409 [10] Dangel L, Koempf D, Fischer SF. Comparison of different commercially available enzyme-
410 linked immunosorbent assays with immunofluorescence test for detection of phase II IgG and
411 IgM antibodies to *coxiella burnetii*. *J Clin Microbiol* 2020;58. doi: 10.1128/JCM.00951-19.

- 412 [11] Wood C, Muleme M, Tan T, Bosward K, Gibson J, Alawneh J, et al. Validation of an indirect
413 immunofluorescence assay (IFA) for the detection of IgG antibodies against *Coxiella burnetii* in
414 bovine serum. *Prev Vet Med* 2019;169: 104698. doi: 10.1016/J.PREVETMED.2019.104698.
- 415 [12] Wilson WC, Weingartl HM, Drolet BS, Davé K, Harpster MH, Johnson PA, et al. Diagnostic
416 Approaches for Rift Valley Fever. *Dev Biol (Basel)* 2013;135: 73–8. doi: 10.1159/000276828.
- 417 [13] Gerken KN, Labeaud AD, Mandi H, Jackson ML, Breugelmans JG, King CH. Paving the way for
418 human vaccination against Rift Valley fever virus: A systematic literature review of RVFV
419 epidemiology from 1999 to 2021. *PLoS Negl Trop Dis* 2022;16. doi:
420 10.1371/JOURNAL.PNTD.0009852.
- 421 [14] Sidi-Boumedine K, Rousset E, Henning K, Ziller M, Niemczuck K, Roest H, et al. Development of
422 harmonised schemes for the monitoring and reporting of Q-fever in animals in the European
423 Union. *EFSA Supporting Publications* 2017;7. doi: 10.2903/SP.EFSA.2010.EN-48.
- 424 [15] Sadiki V, Gcebe N, Mangena ML, Ngoshe YB, Adesiyun AA. Prevalence and risk factors of Q
425 fever (*Coxiella burnetii*) in cattle on farms of Limpopo province, South Africa. *Front Vet Sci*
426 2023;10: 1101988. doi: 10.3389/FVETS.2023.1101988/BIBTEX.
- 427 [16] Natale A, Bucci G, Capello K, Barberio A, Tavella A, Nardelli S, et al. Old and new diagnostic
428 approaches for Q fever diagnosis: Correlation among serological (CFT, ELISA) and molecular
429 analyses. *Comp Immunol Microbiol Infect Dis* 2012;35: 375–9. doi:
430 10.1016/J.CIMID.2012.03.002.
- 431 [17] Kittelberger R, Mars J, Wibberley G, Sting R, Henning K, Horner GW, et al. Comparison of the
432 Q-fever complement fixation test and two commercial enzyme-linked immunosorbent assays
433 for the detection of serum antibodies against *Coxiella burnetii* (Q-fever) in ruminants:
434 Recommendations for use of serological tests on imported animals in New Zealand. *N Z Vet J*
435 2009;57: 262–8. doi: 10.1080/00480169.2009.58619.
- 436 [18] Rousset E, Durand B, Berri M, Dufour P, Prigent M, Russo P, et al. Comparative diagnostic
437 potential of three serological tests for abortive Q fever in goat herds. *Vet Microbiol* 2007;124:
438 286–97. doi: 10.1016/J.VETMIC.2007.04.033.
- 439 [19] Kortekaas J, Kant J, Vloet R, Cêtre-Sossah C, Marianneau P, Lacote S, et al. European ring trial
440 to evaluate ELISAs for the diagnosis of infection with Rift Valley fever virus. *J Virol Methods*
441 2013;187: 177–81. doi: 10.1016/J.JVIROMET.2012.09.016.
- 442 [20] Pawęska JT, van Vuren PJ, Msimang V, Lô MM, Thiongane Y, Mulumba-Mfumu LK, et al. Large-
443 Scale International Validation of an Indirect ELISA Based on Recombinant Nucleocapsid
444 Protein of Rift Valley Fever Virus for the Detection of IgG Antibody in Domestic Ruminants.
445 *Viruses* 2021;13. doi: 10.3390/V13081651.
- 446 [21] Horigan MW, Bell MM, Pollard TR, Sayers AR, Pritchard GC. Q fever diagnosis in domestic
447 ruminants: comparison between complement fixation and commercial enzyme-linked
448 immunosorbent assays. *J Vet Diagn Invest* 2011;23: 924–31. doi:
449 10.1177/1040638711416971.
- 450 [22] Thrusfield M, Christley R, Brown H, Diggle PJ, French N, Howe K, et al. *Veterinary*
451 *Epidemiology: Fourth Edition*. *Veterinary Epidemiology: Fourth Edition* 2017: 1–861. doi:
452 10.1002/9781118280249.

- 453 [23] Fleiss JL, Levin B, Cho Paik M. Statistical Methods for Rates and Proportions, Third Edition.
454 Statistical Methods for Rates and Proportions, Third Edition 2004: 1–760. doi:
455 10.1002/0471445428.
- 456 [24] Altman DG. Practical Statistics for Medical Research. Practical Statistics for Medical Research
457 1990. doi: 10.1201/9780429258589.
- 458 [25] Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.
459 Biometrics 1977;33: 159. doi: 10.2307/2529310.
- 460 [26] Hoehler FK. Bias and prevalence effects on kappa viewed in terms of sensitivity and
461 specificity. J Clin Epidemiol 2000;53: 499–503. doi: 10.1016/S0895-4356(99)00174-2.
- 462 [27] Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol 1993;46: 423–9. doi:
463 10.1016/0895-4356(93)90018-V.
- 464 [28] Lantz CA, Nebenzahl E. Behavior and interpretation of the κ statistic: Resolution of the two
465 paradoxes. J Clin Epidemiol 1996;49: 431–4. doi: 10.1016/0895-4356(95)00571-4.
- 466 [29] Paul S, Toft N, Agerholm JS, Christoffersen AB, Agger JF. Bayesian estimation of sensitivity and
467 specificity of Coxiella burnetii antibody ELISA tests in bovine blood and milk. Prev Vet Med
468 2013;109: 258–63. doi: 10.1016/J.PREVETMED.2012.10.007.
- 469 [30] de Bronsvort BMC, Bagninbom JM, Ndip L, Kelly RF, Handel I, Tanya VN, et al. Comparison of
470 Two Rift Valley Fever Serological Tests in Cameroonian Cattle Populations Using a Bayesian
471 Latent Class Approach. Front Vet Sci 2019;6: 258. doi: 10.3389/FVETS.2019.00258/BIBTEX.
- 472 [31] Emery MP, Ostlund EN, Schmitt BJ. Comparison of Q fever serology methods in cattle, goats,
473 and sheep. J Vet Diagn Invest 2012;24: 379–82. doi: 10.1177/1040638711434943.
- 474 [32] Lurier T, Rousset E, Gasqui P, Sala C, Claustre C, Abrial D, et al. Evaluation using latent class
475 models of the diagnostic performances of three ELISA tests commercialized for the serological
476 diagnosis of Coxiella burnetii infection in domestic ruminants. Vet Res 2021;52. doi:
477 10.1186/S13567-021-00926-W.
- 478 [33] Package “vcd” Title Visualizing Categorical Data 2023. [cited 17 June 2024]. Available from:
479 <https://cran.r-project.org/web/packages/vcd/vcd.pdf>
- 480 [34] Mariner J. Rift Valley fever surveillance. FAO Animal Production and Health Manual No. 21.
481 Food and Agricultural Organizations of the United Nations (FAO). [cited 17 June 2024].
482 Available from: [https://openknowledge.fao.org/server/api/core/bitstreams/4052d2f0-88e5-
483 4a3f-9ae5-049d3c78413c/content](https://openknowledge.fao.org/server/api/core/bitstreams/4052d2f0-88e5-4a3f-9ae5-049d3c78413c/content)
- 484 [35] Field PR, Mitchell JL, Santiago A, Dickeson DJ, Chan S-W, Ho DWT, et al. Comparison of a
485 Commercial Enzyme-Linked Immunosorbent Assay with Immunofluorescence and
486 Complement Fixation Tests for Detection of Coxiella burnetii (Q Fever) Immunoglobulin M. J
487 Clin Microbiol 2000;38: 1645. doi: 10.1128/JCM.38.4.1645-1647.2000.
- 488 [36] Field PR, Santiago A, Chan SW, Patel DB, Dickeson D, Mitchell JL, et al. Evaluation of a novel
489 commercial enzyme-linked immunosorbent assay detecting Coxiella burnetii-specific
490 immunoglobulin G for Q fever prevaccination screening and diagnosis. J Clin Microbiol
491 2002;40: 3526–9. doi: 10.1128/JCM.40.9.3526-3529.2002.

- 492 [37] Sanz JC, De Los Ríos R, Martín F, Ángeles Tébar M, Jado I, Anda P. Aplicación de cuatro
493 técnicas de ELISA (dos para IgM y dos para IgG) en el diagnóstico serológico de un brote de
494 fiebre Q. *Enferm Infecc Microbiol Clin* 2006;24: 178–81. doi: 10.1157/13086551.
- 495 [38] Healy B, Van Woerden H, Raoult D, Graves S, Pitman J, Lloyd G, et al. Chronic Q Fever:
496 Different Serological Results in 3 Countries-Results of a Follow-up Study 6 Years After a Point
497 Source Outbreak. *Clin Infect Dis*. 2011;52: 1013-1019. doi: 10.1093/cid/cir132.
- 498 [39] Ferrara G, Colitti B, Pagnini U, Iovane G, Rosati S, Montagnaro S. Characterization of
499 recombinant Ybgf protein for the detection of Coxiella antibodies in ruminants. *Journal of*
500 *Veterinary Diagnostic Investigation* 2022;34: 646–53. doi: 10.1177/10406387221093581.
- 501 [40] Gerlach C, Škultéty L, Henning K, Neubauer H, Mertens K. Coxiella burnetii immunogenic
502 proteins as a basis for new Q fever diagnostic and vaccine development. *Acta Virol* 2017;61:
503 377–90. doi: 10.4149/AV_2017_320.
- 504 [41] Lippi G, Von Meyer A, Cadamuro J, Simundic AM. Blood sample quality. *Diagnosis (Berl)*
505 2019;6: 25–31. doi: 10.1515/DX-2018-0018.
- 506 [42] Lippi G, Plebani M, Di Somma S, Cervellin G. Critical Reviews in Clinical Laboratory Sciences
507 Hemolyzed specimens: a major challenge for emergency departments and clinical laboratories
508 2011. doi: 10.3109/10408363.2011.600228.
- 509 [43] Edouard S, Million M, Casalta JP, Collart F, Amphoux B, Raoult D. Low antibodies titer and
510 serological cross-reaction between Coxiella burnetii and Legionella pneumophila challenge
511 the diagnosis of mediastinitis, an emerging Q fever clinical entity. *Infection* 2017;45: 911–5.
512 doi: 10.1007/S15010-017-1048-6.
- 513 [44] La Scola B, Raoult D. Serological cross-reactions between Bartonella quintana, Bartonella
514 henselae, and Coxiella burnetii. *J Clin Microbiol* 1996;34: 2270–4. doi:
515 10.1128/JCM.34.9.2270-2274.1996.
- 516 [45] Lukacova M, Melnicakova J, Kazar J. Cross-Reactivity between Coxiella burnetii and
517 Chlamydiae. *Folia Microbiol* 1999;44: 579–84. doi:10.1007/BF02816263.
- 518 [46] Scott RM, Feinsod FM, Allam IH, Ksiazek, TG, Peters CJ, Botros, And BAM, et al. Serological
519 Tests for Detecting Rift Valley Fever Viral Antibodies in Sheep from the Nile Delta. *J Clin*
520 *Microbiol* 1986;24: 612–4. doi: 10.1128/jcm.24.4.612-614.1986.
- 521 [47] Swanepoel R, Struthers JK, Erasmus MJ, Shepherd SP, McGillivray GM, Erasmus BJ, et al.
522 Comparison of techniques for demonstrating antibodies to Rift Valley fever virus. *J Hyg (Lond)*
523 1986;97: 317–29. doi: 10.1017/S0022172400065414.
- 524 [48] Szymczak MS, Reeves WK, Miller MM. Further Characterization of Rio Grande Virus and
525 Potential for Cross Reactivity with Rift Valley Fever Virus Assays. *Viruses* 2021;13. doi:
526 10.3390/V13091719.
- 527 [49] Edouard S, Mahamat A, Demar M, Abboud P, Djossou F, Raoult D. Comparison between
528 emerging Q fever in French Guiana and endemic Q fever in Marseille, France. *Am J Trop Med*
529 *Hyg* 2014;90: 915–9. doi: 10.4269/AJTMH.13-0164.
- 530 [50] Tumusiime D, Isingoma E, Tashoroora OB, Ndumu DB, Bahati M, Nantima N, et al. Mapping
531 the risk of Rift Valley fever in Uganda using national seroprevalence data from cattle, sheep
532 and goats. *PLoS Negl Trop Dis* 2023;17: e0010482. doi: 10.1371/JOURNAL.PNTD.0010482.

- 533 [51] Murphy AM, Field PR. The persistence of complement-fixing antibodies to q-fever (coxiella
534 burneti) after infection. *Medical Journal of Australia* 1970;1: 1148–50. doi: 10.5694/J.1326-
535 5377.1970.TB84481.X.
- 536 [52] Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus (Bunyaviridae:
537 Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and
538 prevention. *Vet Res* 2010;41. doi: 10.1051/VETRES/2010033.
- 539 [53] Brown RD, Scott GR, Dalling T. Persistence of antibodies to rift valley fever in man. *The Lancet*
540 1957;270: 345. doi: 10.1016/S0140-6736(57)92243-2.
- 541 [54] Sukocheva OA, Marmion BP, Storm PA, Lockhart M, Turra M, Graves S. Long-term persistence
542 after acute Q fever of non-infective *Coxiella burnetii* cell components, including antigens. *QJM*
543 2010;103: 847–63. doi: 10.1093/QJMED/HCQ113.
- 544 [55] Marmion BP, Sukocheva O, Storm PA, Lockhart M, Turra M, Kok T, et al. Review Q fever:
545 persistence of antigenic non-viable cell residues of *Coxiella burnetii* in the host-implications
546 for post Q fever infection fatigue syndrome and other chronic sequelae. *QJM*. 2009;102(10):
547 673-684. doi:10.1093/qjmed/hcp077.
- 548 [56] Stellfeld M, Gerlach C, Richter IG, Miethe P, Fahlbusch D, Polley B, et al. Evaluation of the
549 Diagnostic Potential of Recombinant *Coxiella burnetii* Com1 in an ELISA for the Diagnosis of Q
550 Fever in Sheep, Goats and Cattle. *Microorganisms* 2020;8: 1–19. doi:
551 10.3390/microorganisms8081235.
- 552 [57] Mehraj V, Textoris J, Capo C, Raoult D, Leone M, Mege JL. Overexpression of the per2 gene in
553 male patients with acute Q fever. *Journal of Infectious Diseases* 2012;206: 1768–70. doi:
554 10.1093/INFDIS/JIS600.
- 555 [58] Gay L, Melenotte C, Lopez A, Desnues B, Raoult D, Leone M, et al. Impact of Sex Hormones on
556 Macrophage Responses to *Coxiella burnetii*. *Front Immunol* 2021;12: 5510. doi:
557 10.3389/FIMMU.2021.705088/BIBTEX.
- 558 [59] Leone M, Honstetter A, Lepidi H, Capo C, Bayard F, Raoult D, et al. Effect of sex on *Coxiella*
559 *burnetii* infection: protective role of 17beta-estradiol. *J Infect Dis* 2004;189: 339–45. doi:
560 10.1086/380798.
- 561 [60] Schoffelen T, Wong A, Rümke HC, Netea MG, Timen A, van Deuren M, et al. Adverse events
562 and association with age, sex and immunological parameters of Q fever vaccination in
563 patients at risk for chronic Q fever in the Netherlands 2011. *Vaccine* 2014;32: 6622–30. doi:
564 10.1016/J.VACCINE.2014.09.061.
- 565